---
title: "諾和諾德產品與投資組合戰略主管赫爾戈特：與競爭對手禮來的減肥藥相比，司美格魯肽口服片具有非常有吸引力的優勢。"
description: "諾和諾德產品與投資組合戰略主管赫爾戈特：與競爭對手禮來的減肥藥相比，司美格魯肽口服片具有非常有吸引力的優勢。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/257694839.md"
published_at: "2025-09-17T09:39:30.000Z"
---

# 諾和諾德產品與投資組合戰略主管赫爾戈特：與競爭對手禮來的減肥藥相比，司美格魯肽口服片具有非常有吸引力的優勢。

諾和諾德產品與投資組合戰略主管赫爾戈特：與競爭對手禮來的減肥藥相比，司美格魯肽口服片具有非常有吸引力的優勢。

### Related Stocks

- [NVO.US - 諾和諾德公司](https://longbridge.com/zh-HK/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/zh-HK/news/276447697.md) |
| Novo Nordisk Proposes Two Additional New Board Appointments | Danish pharmaceutical company Novo Nordisk is proposing three new appointments to its board of directors for the annual  | [Link](https://longbridge.com/zh-HK/news/276442777.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/zh-HK/news/276280378.md) |
| Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | [Link](https://longbridge.com/zh-HK/news/276440991.md) |
| Novo Nordisk: Will Have Replacements for Ozempic and Wegovy Ready When Patents Expire - Berlingske | Danish pharmaceutical company Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their paten | [Link](https://longbridge.com/zh-HK/news/276314777.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。